For example, eteplirsen, which targets exon 51 of dystrophin pre‐mRNA, restores the translational reading frame and is approved for Duchenne muscular dystrophy (DMD) treatment.[37] Additionally, nusinersen, an ASO drug targeting Survival motor neuron‐2 (SMN‐2) mRNA has been approved for the treatment of spinal muscular atrophy (SMA).[38] Notably, the current treatments for skin fibrosis are limited and often ineffective, making ALKBH3‐targeted therapy a valuable therapeutic approach. Here, DMD is linked to spinal muscular atrophy.